OrbiMed Capital GP VII LLC
CIK 1760648
Transactions on file
29
Open-market buys
6
Win rate (buys)
100%
6 scored
Avg % since filing (buys)
+326.2%
Tickers traded
Recent activity
| Filed | Txn date | Issuer | Roles | Code | Shares | Value | % since Filing | Filing |
|---|---|---|---|---|---|---|---|---|
| 2026-06-24 | 2026-06-22 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 46,776 | $2.10M | +19.5% | open → |
| 2026-06-24 | 2026-06-22 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 787,024 | $35.72M | +18.5% | open → |
| 2026-06-24 | 2026-06-22 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 1,477 | $66.5K | +19.5% | open → |
| 2026-06-24 | 2026-06-22 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 24,846 | $1.13M | +18.5% | open → |
| 2026-06-17 | 2026-06-15 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 272,322 | $12.26M | +19.4% | open → |
| 2026-06-17 | 2026-06-15 | ELVN Enliven Therapeutics, Inc. | 10% | Sale | 9,086 | $409.1K | +19.4% | open → |
| 2026-06-02 | 2026-05-28 | QTTB Q32 Bio Inc. | Director10% | Buy | 625,000 | $5.00M | +96.4% | open → |
| 2026-06-02 | 2026-05-28 | QTTB Q32 Bio Inc. | Director10% | Buy | 1,250,000 | $10.00M | +96.4% | open → |
| 2025-01-08 | 2025-01-08 | PASG Passage BIO, Inc. | 10% | Sale | 75,007 | $51.0K | +579.4% | open → |
| 2025-01-08 | 2025-01-07 | PASG Passage BIO, Inc. | 10% | Sale | 52,536 | $37.3K | +550.7% | open → |
| 2025-01-08 | 2025-01-06 | PASG Passage BIO, Inc. | 10% | Sale | 19,481 | $15.0K | +500.0% | open → |
| 2025-01-14 | 2025-01-14 | PASG Passage BIO, Inc. | 10% | Sale | 79,024 | $47.4K | +670.0% | open → |
| 2025-01-14 | 2025-01-10 | PASG Passage BIO, Inc. | 10% | Sale | 126,209 | $83.3K | +600.0% | open → |
| 2025-01-14 | 2025-01-13 | PASG Passage BIO, Inc. | 10% | Sale | 17,986 | $11.5K | +621.9% | open → |
| 2025-02-19 | 2025-02-14 | MBX MBX Biosciences, Inc. | Director10% | Buy | 29,540 | $291.0K | +467.7% | open → |
| 2025-02-19 | 2025-02-18 | MBX MBX Biosciences, Inc. | Director10% | Buy | 49,070 | $531.9K | +415.9% | open → |
| 2025-02-19 | 2025-02-14 | MBX MBX Biosciences, Inc. | Director10% | Buy | 17,962 | $177.8K | +464.8% | open → |
| 2025-02-19 | 2025-02-18 | MBX MBX Biosciences, Inc. | Director10% | Buy | 94,100 | $1.02M | +415.9% | open → |
| 2025-04-17 | 2025-04-17 | PASG Passage BIO, Inc. | 10% | Sale | 77,090 | $25.4K | +1300.0% | open → |
| 2025-04-17 | 2025-04-16 | PASG Passage BIO, Inc. | 10% | Sale | 61,638 | $20.3K | +1300.0% | open → |
| 2025-04-17 | 2025-04-15 | PASG Passage BIO, Inc. | 10% | Sale | 10,326 | $3.9K | +1115.8% | open → |
| 2025-04-24 | 2025-04-22 | PASG Passage BIO, Inc. | 10% | Sale | 78,049 | $26.5K | +1258.8% | open → |
| 2025-04-24 | 2025-04-23 | PASG Passage BIO, Inc. | 10% | Sale | 89,328 | $30.4K | +1258.8% | open → |
| 2025-04-24 | 2025-04-24 | PASG Passage BIO, Inc. | 10% | Sale | 68,195 | $21.8K | +1343.8% | open → |
| 2025-06-26 | 2025-06-25 | PASG Passage BIO, Inc. | 10% | Sale | 138,800 | $45.8K | +1300.0% | open → |
| 2025-06-26 | 2025-06-26 | PASG Passage BIO, Inc. | 10% | Sale | 213,257 | $70.4K | +1300.0% | open → |
| 2025-06-26 | 2025-06-24 | PASG Passage BIO, Inc. | 10% | Sale | 231,600 | $81.1K | +1220.0% | open → |
| 2025-12-18 | 2025-11-21 | KROS Keros Therapeutics, Inc. | Director | Disp. | 74,465 | $1.32M | -43.3% | open → |
| 2025-12-18 | 2025-11-21 | KROS Keros Therapeutics, Inc. | Director | Disp. | 140,057 | $2.49M | -43.3% | open → |
